Nuveen Asset Management LLC Cuts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Nuveen Asset Management LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 30.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 475,630 shares of the biopharmaceutical company’s stock after selling 211,009 shares during the quarter. Nuveen Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $338,806,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Regeneron Pharmaceuticals by 2.1% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 82,519 shares of the biopharmaceutical company’s stock valued at $58,774,000 after purchasing an additional 1,712 shares during the last quarter. Mmbg Investment Advisors CO. purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth $264,000. Lazard Asset Management LLC grew its holdings in Regeneron Pharmaceuticals by 22.8% in the fourth quarter. Lazard Asset Management LLC now owns 19,912 shares of the biopharmaceutical company’s stock worth $14,183,000 after purchasing an additional 3,696 shares during the last quarter. Lighthouse Investment Partners LLC purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth $2,351,000. Finally, Investment Management Corp of Ontario grew its holdings in Regeneron Pharmaceuticals by 43.5% in the fourth quarter. Investment Management Corp of Ontario now owns 5,149 shares of the biopharmaceutical company’s stock worth $3,668,000 after purchasing an additional 1,562 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 0.5%

Regeneron Pharmaceuticals stock opened at $571.36 on Thursday. The firm has a market cap of $62.46 billion, a price-to-earnings ratio of 14.93, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a 52 week low of $520.50 and a 52 week high of $1,211.20. The business’s 50-day moving average price is $605.64 and its 200 day moving average price is $689.30. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the previous year, the business earned $9.55 EPS. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.62%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.96%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on REGN. Bernstein Bank dropped their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. UBS Group dropped their price target on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 30th. Citigroup raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $600.00 to $700.00 in a research report on Wednesday. TD Cowen dropped their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. Finally, Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $890.60.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.